About

Bone health also favoured the patches, with fractures roughly twice as common in the injection group. Because injections strip away oestrogen as well as testosterone, they create a kind of sudden "male menopause", complete with hot flushes, night sweats and thinning bones. They are effective, but they are blunt tools, dragging down oestrogen as well as testosterone and taking a heavy toll on quality of life with hot flushes, brittle bones and metabolic problems. For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices. Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited.
According to this model, depriving PCa of testosterone can cause tumor death. However, data does show that low testosterone does not protect men from developing PCa. Later, many researchers looked for a link between high testosterone and PCa, but found no conclusive results. However, this study only reported results for 2 men, one of whom was castrated. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit…" Putative risks include edema and worsening of sleep apnea.
Two of the trials and one meta-analysis pointed to an increased risk of cardiovascular events,363, 364, 366 two revealed no cardiovascular risk,233, 367 and one was neutral with respect to risk.373 The Corona meta-analysis,372 which showed that there was no increased risk of cardiovascular events, was not officially reviewed but was taken into consideration in the final analysis. SQ testosterone pellets were initially developed and FDA approved in 1972 and were reformulated in the USA in 2008. Long-acting IM testosterone injection may also result in higher rates of polycythemia when compared to topical therapies, which is consistent with other short-acting  IM testosterone therapies. Mild level adverse events specific to SQ pellet insertion includes polycythemia (48-50%), ecchymosis (32-36%), tenderness (20-32%), pain (28-29%), and swelling (16-18%), all of which resolve by 4 months post-insertion.446 Moderate level adverse events were less common (e.g., pain 3%, erythema 3%, ecchymoses 7%) and improved within 1 week. These recommendations, however, are not based on current testosterone pellet formulations and contrast with pharmacokinetic data available. The unique pharmacokinetic profile of testosterone pellets is due to their crystalline structure, which dissolves slowly in SQ spaces.
Testosterone is an essential part of reproductive health. It affects male fetuses as they develop in the uterus, as well as teenage sexual development during puberty. Testosterone deficiency during fetal development doesn’t allow male characteristics to develop normally. Late-onset hypogonadism affects about 2% of men over the age of 40. This condition is very common — up to 15% of females of reproductive age have it.
The main purpose of testosterone therapy is to return patients to normal physiological testosterone levels and provide relief of symptoms or signs. In patients who have two PSA levels at baseline that raise suspicion for the presence of prostate cancer, a more formal evaluation, potentially including reflex testing (e.g., 4K or phi), and prostate biopsy with/without MRI, should be considered before initiating testosterone therapy. PSA secretion is an androgen dependent phenomenon, and the rise of PSA levels in patients on testosterone therapy is primarily dependent upon baseline total testosterone levels. Patients with testosterone deficiency and a history of prostate cancer should be informed that there is inadequate evidence to quantify the risk-benefit ratio of testosterone therapy. Dr. Afshar, with his extensive experience in both men’s health and prostate cancer care, encourages men to seek evidence-based information and comprehensive evaluation when considering testosterone therapy.

Female